Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements
On November 12, 2025, The Fly reported that Barclays reduced its price target on Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) from $12 to $11, while maintaining an “Overweight” rating.


